Publications by authors named "Y Takama"

Article Synopsis
  • The JPLT3-S study examined the effectiveness of cisplatin (CDDP) monotherapy for young children with standard-risk hepatoblastoma, aiming to reduce treatment toxicity compared to previous studies.
  • A total of 38 patients under 3 years old participated, achieving a remarkable 3-year progression-free survival rate of 93.9% and a 100% overall survival rate.
  • Despite the positive outcomes, nearly half of the patients experienced late-onset ototoxicity, highlighting a potential side effect of CDDP treatment.
View Article and Find Full Text PDF

Purpose: To determine an early diagnostic indicator of biliary atresia (BA), we focused on morphological left-right differences of BA livers.

Methods: Of 74 infants with suspected BA at our hospital in the last 12 years, 25 met the conditions for investigation: 15 infants with BA (BA group) and 10 with other pathologies (non-BA group). CT volumetry of the liver in each patient was performed using a 3D image analysis system.

View Article and Find Full Text PDF

In the JPLT3 study, a real-time central surgical reviewing (CSR) system was employed aimed at facilitating early referral of candidates for liver transplantation (LTx) to centers with pediatric LTx services. The expected consequence was surgery, including LTx, conducted at the appropriate time in all cases. This study aimed to review the effect of CSR on institutional surgical decisions in cases enrolled in the JPLT3 study.

View Article and Find Full Text PDF

In a series of studies, using an identical rat intestinal transplantation model, we evaluated the effects of several drugs. FK-506 caused a significant attenuation in the proliferation of allogeneic CD4+ T cells and IFN-γ secreting effector functions. FYT720 resulted in a marked reduction in the numbers of lymphocytes, associated with a reduction of T cell recruitment, in grafts.

View Article and Find Full Text PDF

Purpose: In 2004, the Japanese government halted nationwide mass screening for neuroblastoma in 6-month-old infants as it led to overdiagnosis of localized tumors with favorable prognoses and failed to reduce neuroblastoma-related mortality. However, a new mass screening program for neuroblastoma in 18-month-old infants (18MS) was conducted in the Osaka prefecture. We assessed the efficacy of the 18MS in screening unfavorable cases.

View Article and Find Full Text PDF